1. Home
  2. NAMS vs MLCO Comparison

NAMS vs MLCO Comparison

Compare NAMS & MLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • MLCO
  • Stock Information
  • Founded
  • NAMS 2019
  • MLCO 2004
  • Country
  • NAMS Netherlands
  • MLCO Hong Kong
  • Employees
  • NAMS N/A
  • MLCO N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • MLCO Hotels/Resorts
  • Sector
  • NAMS Health Care
  • MLCO Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • MLCO Nasdaq
  • Market Cap
  • NAMS 2.7B
  • MLCO 2.4B
  • IPO Year
  • NAMS N/A
  • MLCO 2006
  • Fundamental
  • Price
  • NAMS $18.57
  • MLCO $6.01
  • Analyst Decision
  • NAMS Strong Buy
  • MLCO Buy
  • Analyst Count
  • NAMS 7
  • MLCO 6
  • Target Price
  • NAMS $41.33
  • MLCO $7.83
  • AVG Volume (30 Days)
  • NAMS 646.5K
  • MLCO 4.4M
  • Earning Date
  • NAMS 03-04-2025
  • MLCO 03-03-2025
  • Dividend Yield
  • NAMS N/A
  • MLCO N/A
  • EPS Growth
  • NAMS N/A
  • MLCO N/A
  • EPS
  • NAMS N/A
  • MLCO N/A
  • Revenue
  • NAMS $33,594,000.00
  • MLCO $4,540,808,000.00
  • Revenue This Year
  • NAMS $131.53
  • MLCO $25.13
  • Revenue Next Year
  • NAMS N/A
  • MLCO $4.74
  • P/E Ratio
  • NAMS N/A
  • MLCO N/A
  • Revenue Growth
  • NAMS 78.77
  • MLCO 50.42
  • 52 Week Low
  • NAMS $15.19
  • MLCO $4.78
  • 52 Week High
  • NAMS $27.29
  • MLCO $8.90
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 29.65
  • MLCO 55.20
  • Support Level
  • NAMS $18.88
  • MLCO $6.04
  • Resistance Level
  • NAMS $20.46
  • MLCO $6.28
  • Average True Range (ATR)
  • NAMS 1.11
  • MLCO 0.25
  • MACD
  • NAMS -0.09
  • MLCO 0.08
  • Stochastic Oscillator
  • NAMS 5.84
  • MLCO 71.67

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About MLCO Melco Resorts & Entertainment Limited

Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 82.5% from Macao with the rest largely from the Philippines as of first-half 2024.

Share on Social Networks: